Loma Linda University

TheScholarsRepository@LLU: Digital Archive of Research,
Scholarship & Creative Works
Loma Linda University Electronic Theses, Dissertations & Projects
6-1984

The Effect of Dietary Alpha - Linolenic Acid on Apparent Risk
Factors of Cardiovascular Disease
Kelvin D. Lindbeck

Follow this and additional works at: https://scholarsrepository.llu.edu/etd
Part of the Biochemical Phenomena, Metabolism, and Nutrition Commons, Nutrition Commons, and
the Vital and Health Statistics Commons

Recommended Citation
Lindbeck, Kelvin D., "The Effect of Dietary Alpha - Linolenic Acid on Apparent Risk Factors of
Cardiovascular Disease" (1984). Loma Linda University Electronic Theses, Dissertations & Projects. 1544.
https://scholarsrepository.llu.edu/etd/1544

This Thesis is brought to you for free and open access by TheScholarsRepository@LLU: Digital Archive of
Research, Scholarship & Creative Works. It has been accepted for inclusion in Loma Linda University Electronic
Theses, Dissertations & Projects by an authorized administrator of TheScholarsRepository@LLU: Digital Archive of
Research, Scholarship & Creative Works. For more information, please contact scholarsrepository@llu.edu.

Abstract
THE EFFECT OF DIETARY ALPHA - LINDLENIC ACID ON APPARENT RISK
FACTORS OF CARDIOVASCULAR DISEASE
by
Kelvin D. Lindbeck

Eight healthy male lacto-ovo-vegetarian subjects averaging 28.0 ±
3.6 years of age (22 to 53 years) were fed a diet rich in a-linolenic
acid (18:3o)3) for four weeks. Arterial blood pressure and body weight
were recorded each week. Plasma 6-keto-prostaglandin F-^ (6-ketoPGFn

La

), thromboxane B0 (TXB0), total cholesterol, triglyceride, and
t-

total phospholipid fatty acid composition were analysed at 0, 2 and 4
weeks.
Systolic blood pressure Increased significantly between weeks 0
and 1 (106.5 t 2.7 nniHg to 114.0 t 3.7 mmHg; p<0.003), but decreased
to 107.3 t 2.6 mrHg (p<0.02) at week 2. There was an insignificant
increase in both systolic and diastolic blood pressures after four
weeks. There was no significant change in either total cholesterol or
triglyceride levels during the four weeks.
Plasma 6-keto-PGFlQ, levels increased significantly from 60.13

t

8.50 pg/ml to 288.75 ± 33.44 pg/nd (p<0.001) during the four weeks.
Plasma TXE^ levels increased during the first two weeks (397.50 ±

25.34 pg/ml to 1576.25 ± 282.61 pg/ml; p<0.005) then decreased to
814.29 t 122.74 pg/ml (p<0.02) at week 4.
Plasma total phospholipid fatty acid analysis revealed a decrease
in 18:2CJ6 (p<0.04), and an increase in 18:3a>3 (p<0.02) and 20:5u>3
(p<0.02) during the four week study.
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CHAPTER ONE
LITERATURE REVIEW
Introduction
During the mid-1960 Ts, linolenic acid (LNA) and linseed oil (a
major source of LNA) were extensively used In research, as evidence
suggested they might have beneficial effects in preventing platelet
aggregation and coronary thrombosis. This implied that they may have a
role in the prevention of atherosclerosis and coronary heart disease.
At that time, very little was known about the prostaglandins, and
prostacyclin (PG^) and thromboxane

were unknown substances.

Over the past few years, PGI2 and TXA^ have been implicated in
having a role in the formation or prevention of atherosclerosis and
coronary heart disease by regulation of platelet activity, thereby
controlling thrombosis (or the clotting mechanism).
It has recently been shown that eicosapentaenoic acid (EPA) may
reduce the occurrence of coronary heart disease in Eskimos by modifying
the rate of synthesis of PGI2 and

Since LNA is converted into EPA

within the human' body via the desaturase and elongation system, it is
reasonable to anticipate the same results with LNA as with EPA.
The objective of the research performed was to investigate the
effect of LNA on a) blood pressure, b) plasma total phospholipid fatty
acid composition, c) plasma TXB2 and 6-keto-PGF-^levels, and d) plasma
triglyceride and total cholesterol levels.
The goals of this research project are to determine if LNA may be
beneficial in the prevention and treatment of atherosclerosis and
coronary heart disease.
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Essential Fatty Acids
Linolenic acid (INA, 18:3 co 3) is a polyunsaturated fatty acid with
a carbon skeleton of 18 and three double bonds (figure 1), and is the
precursor of the CJ-3 series of fatty acids, which includes eicosapentaenoic acid (EPA, 20:5 a? 3)(figure 1).
There is evidence to suggest that, in conjunction with linoleic
acid (LA, 18:2 co 6), INA serves to make up the essential fatty acids
necessary for growth and maintenance of human life (1). The w -3 fatty
acids are important conponents of menbrane-based lipids in many body
tissues, particularly nervous tissue (2). There have been reports that
CJ-3 deficiency may result in physiological changes which can be

reversed on feeding INA (3). Tinoco et al.(4), however, were unable to
demonstrate the classical deficiency symptoms of INA-deficiency in
rats, namely those affecting appearance, growth or reproduction.
Linolenic acid is not as abundant in foods as LA, but is found in
abundance in linseed oil (50 to 60%), and in lesser amounts in soybeans
(7%), walnuts (7 to 8%), rapeseed (97o), wheatgerm (67>) and millett (6%)
(5).
Linoleic acid is also a polyunsaturated fatty acid with a carbon
skeleton of 18 but with only two double bonds (figure 1). It belongs to
the w-6 series of fatty acids, which also includes arachidonic acid
(AA, 20:4(j)6)(figure 1). LA is found in abundance in plant products,
particularly grain and vegetable oils (5).
Fatty Acid Desaturase and Elongation System
Fatty acids may undergo desaturation and elongation within the

Figure 1. The structure of the first two members of the 0-6 and <^-3
families of fatty acids.

18:2 w6
LINOLEIC ACID

20-4W6
ARACHIDONIC ACID

18:3 u) 3
LINOLENIC ACID

20:5 lO 3
EICOSAPENTAENOIC ACID
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body before being incorporated into tissue phospholipids. Ihis
desaturation and elongation occurs within the microsomes (6), with the
rate-limiting step being the initial desaturation by the A6 desaturase
enzyme (7). Both LA and LNA undergo desaturation and elongation by the
same enzyme system to produce the subsequent fatty acids of the CJ-6
and cu-3 families respectively (figure 2) (18).
Numerous studies have indicated that the dietary levels of these
acids affects the degree of desaturation and elongation. Studies have
shown that dietary LNA. reduces the level of tissue fatty acids derived
from LA (8). By increasing the intake of LNA., a decrease in the
subsequent fatty acid derivatives of the to-6 family occurs, while the
to-3 family fatty acid derivatives increase (7-11). From these studies,
the data indicates that A6 desaturase prefers to -3 fatty acids to co -6
fatty acids as substrate (7).
Prostaglandins and Prostanoids
Prostaglandins (PGs) are a group of naturally occurring,
chemically related, polyunsaturated, hydroxylated long-chain fatty acid
derivatives that have a wide spectrum of biological actions at low
concentrations in a variety of tissues (12).
Prostaglandins occur in minute quantities in many tissues, and
have been implicated as playing functional roles in many physiological
processes including vasodilation, vasoconstriction, platelet
aggregation, inflammation, reproduction, and renal and gastrointestinal
function (12).
Prostacyclin (PCB^) and thromboxanes (TXs), although not exactly

Figure 2. A schematic diagram of the steps involved in the
desaturation and elongation of

to-6

and qj-3 fatty acids.
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PGs, are related compounds, and are hence termed prostanoids, since
they possess a similar structure and biosynthesis as the PGs (figures
3a, b, c and 4).
Prostaglandin and Prostanoid Biosynthesis
Because PGs are not stored within the body to any great extent
(12), it is necessary for the body to synthesize the particular PG or
prostanoid when needed. To do so, the body must have available the
necessary precursor(s) for the tissue synthesizing the specific PG or
prostanoid required. The principle precursor required for PG and
prostanoid biosynthesis is AA (figure 4) (12).
Arachidonic acid for PG biosynthesis may be derived from two
sources - a) dietary AA, or b) from LA via microsomal desaturation and
elongation. Although the body does not store PGs, the precursor
substrate, AA, is stored in tissues, generally as phospholipids bound
to cell merrbranes (12). "When needed, the AA is selectively deacylated
by phospholipases, mainly phospholipase

to provide the free

substrate for PG and prostanoid biosynthesis. The importance of
phospholipase ^ can be seen when one considers that the rate-limiting
step in PG synthesis is substrate availability. Of the several steps
involved in the biosynthetic pathway, this is the most important (12).
After the free AA has been liberated it can then follow one of two
pathways in its metabolism (figure 4). It may be hydroxylated by fatty
acid lipoxygenase to form hydroxy acids such as hydroxyeicosatetraenoic
acid (HETE) and hydroxyperoxyeicosatetraenoic acid (HPETE) (12).
Alternatively, AA may interact with a merrbrane-bound multienzyme

9

Figure 3a. The structure of some of the prostaglandin endoperoxides
and prostaglandins.
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Figure 3b. The structure of prostacyclin and its stable metabolite
6-keto-prostaglandin Fla.
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Figure 3c. The structure of thromboxane
thromboxane
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Figure 4.

A schematic cH agram of the biosynthesis of the

prostaglandins and prostanoids from arachidomc acid.
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complex, PG endoperoxide synthetase, that catalyzes the formation of
the 15-hydroxyprostaglandin endoperoxides - prostaglandin G2 (PGG2) and
prostaglandin ^(PG^) (figure 3a) - through the incorporation of
molecular oxygen into the fatty acid (12).
The endoperoxide synthetase consists of two fractions - a) the
cyclooxygenase fraction, responsible for the formation of PGG2 and
dependent on L-tryptophan and hemoglobin for maximal activity, and
b) the isomerase (peroxidase) fraction, responsible for the formation
of PGH2 and requiring glutathione for its action. PG^ then serves as
the conmon precursor for the formation of the PGs and prostanoids
(figure 4) (12).
A number of compounds, such as catecholamines, hydroquinone,
L-tryptophan and serotonin, are considered essential cofactors for PG
biosynthesis, performing as catalysts for the endoperoxide synthetase
reactions (12).
Some agents, particularly drugs, affect specific steps of PG
biosynthesis. Phospholipase

activity is inhibited by glucocorticoids

a nunber of local anesthetics (such as mepacrlne and bromophenacetyl
bromide) and numerous steroidal antiinflammatory drugs (13). Although
the mechanism by which many of these agents inhibit phospholipase
activity is unknown, the action of glucocorticoids is thought to be via
the synthesis of a peptide or protein which is directly responsible for
the inhibition. The glucocorticoids Interact with receptors in the
cytosol and through transcriptional and translational steps, induce the
synthesis of the inhibiting peptide or protein (13).
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The formation of the PGs is also inhibited by non-steroidal antiinflanmatory drugs such as aspirin, indomethacin and dipyridamole (13).
These agents work by inhibiting cyclooxygenase activity. The cyclooxygenase of blood platelets appears to be highly sensitive to the
action of aspirin. The inhibitory action of aspirin is via the
irreversible acetylation of an active site of the platelet enzyme (14).
Since platelets possess no nuclei and are incapable of synthesizing
enzymatic proteins, the inhibition persists up to the end of the
platelet lifetime in the circulatory system. This impairment of
platelet function, though persistent, is mild and cannot be enhanced by
an increased dosage (13).
Indonethacin has a considerably briefer period of action on the
platelets than that of aspirin, as the inhibition appears to be
soirewhat reversible (15). Zinc and calcium ions have an effect on
cyclooxygenase similar to that of indomethacin (13). Vitamin E is known
to attenuate the formation of PGs (13) and along with its fully
oxidized form, tocopherol quinone, is a known inhibitor of platelet
aggregation (16).
Prostacyclin and Thromboxane
Both PG^ and

are synthesized from PGH^ through the action of

specific synthetases - PGI2 synthetase and TX synthetase respectively
(figure 4) (13).
PGI2 synthetase in the pig aorta and rat stomach has been shown to
be inhibited by auto-oxidized PA and 15-hydroperoxyarachidonic acid
(17). This suggests that excessive peroxidation of lipids would lead to
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suppression of PGI2 synthetase activity, and a reduction in the
potential to form PGI2. Nicotine also has a suppressive action on the
activity of PGI2 synthetase (12).
Prostacyclin formation occurs primarily in the intimal region of
arterial tissue, although there is evidence that other tissues can
produce

It is an unstable substance, with a plasma half-life of

30 minutes, and is spontaneously broken down to 6-keto-prostaglandin
(6-keto-PGF^ ), the stable metabolite of PGI2 (figure 3b). This
decomposition is dependent on pH and temperature, with decomposition
being enhanced by low pH and increased temperature (12).
Prostacyclin has three definite physiological actions. These are
a) platelet anti-aggregation, b) vasodilation, and c) relaxation of
smooth muscle. In addition to these actions, it also functions in
cytoprotection (ulcer prevention) (Table 1; 13, 18).
Thromboxane

seems to work as an antagonist to PG^. The major

actions of TXA2 are a) platelet aggregation, b) vasocostriction, and
c) smooth muscle contraction. It also has a role in the promotion of
inflammation (Table 1; 18). IX synthetase activity may be inhibited by
imidazole (a stimulator of cyclic AMP phosphodiesterase) (13), and zinc
and cadmium ions (12).
Because many of the antagonistic functions of PGI2 and TXA2
involve the cardiovascular system they have been implicated, in part,
as possibly being involved in the onset of cardiovascular disease. The
subtle balance between TXA2 and PGI2 may be perturbed by a number of
factors. If the arteriole walls become coated with fat deposits or

20

Table 1. A surmary of the physiological properties of prostacyclin
and thromboxane P^.

* platelet anti-aggregation

* platelet aggregation

* vasodilation

* vasoconstriction

* smooth muscle relaxation

* smooth miscle contraction

* decrease blood pressure

* increase blood pressure

* cytoprotection

* inflammation
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plaque, thrombus formation may not be counteracted by the formation of
PGI2 because the endothelial tissue containing the enzymes necessary
for conversion of PO^ to PGI2 is covered. The thrombus, together with
TXA^induced vasoconstriction and the presence of plaque on the
interior of the arteriole, may result in the clogging of the arteriole,
the restriction of bloodflow, and possible occlusion and thrombosis

(18).
The balance between PGI2 and TX^ also have a bearing on blood
pressure regulation. Since PGI2 is a vasodilator and TXA^ is a
vasoconstrictor, they may exert their effect on blood pressure through
these actions. Thus, PGI2 decreases arterial blood pressure and TX^
increases arterial blood pressure (Table 1; 18).
Prostacyclin may exert its hypotensive effect on blood pressure
through another mechanism as well - that of the angiotensin-renin
system of the renal system (13). PGI2 has been found to be a principal
product of the renal vasculature, and is known to be a potent
vasodilator of the renal blood vessels (13). Its synthesis is
stimulated by angiotensin II, and upon its release causes an increase
in renal bloodflow and sodium excretion (13), probably through its
vasodilating properties. So it is that a potent vasoconstrictor angiotensin II - stimulates the production of a potent - PGI2. The
interaction of these two substances may greatly affect the regulation
of blood pressure.
Although known to have a vasoconstricting action on the renal
vasculature, 12^ does not appear to have a very influential effect on
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blood pressure by controlling renal bloodflow. Its synthesis in renal
tissue has not been identified in any substantial quantity. If present
though, it is conceivable that TX^ may decrease renal bloodflow and
sodium excretion through its vasoconstrieting action (13). TX^ may
still exert an effect on blood pressure regulation by the kidneys
through that produced by the platelets in the renal circulation.
I|
Ionic calcium (Ca )may be involved in the mechanisms by which
TXA2 and PGI2 exert their effect on the cardiovascular system. Theories
have been put forward proposing an ionophoretic ability of PG action
|
I
(13). Interrelationships between Ca and PGs are by no means clear,
but it is becoming increasingly evident that PGs may exert many of
their actions through alteration of Ca

|
I

metabolism. PGs are capable of

forming metastable calcium complexes in aqueous solutions (13).
-H-

Ihromboxane ^ appears to be intrinsic to the control of Ca

flux

(19), and there is some direct experimental evidence of Ca*"** mobiliz||

ation by TX^. There exists a possibility that the free Ca

concen

tration may modulate TXA^ biosynthesis, since it is well documented
I1
that the majority of phospholipases exhibit a clear Ca dependence
(13).
Since Ca

]|

is also involved in platelet aggregation and clotting

(20), muscle contraction (20), and blood pressure regulation (21), it
|
I
seems possible that modulation of the Ca flux may be an ideal way for
PGI2 and 1X^2 to exert their effects. This interaction between the
I|
prostanoids and Ca may include interactions with cyclic AMP (13).
Gorman et al.(22) have offered a hypothesis for the mechanism of
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the proaggregatory action of TX^. It is proposed that IXA2 mobilizes
|
|
Ca within the platelet, possibly from the dense tubular system. Once
11
nobilized, the Ca inhibits adenylate cyclase which, in turn, causes a
|
I
fall in cyclic (cAMP). Since cAMP enhances Ca sequestration and
inhibits phospholipase

activity, the TXA2-induced fall in cAMP

causes a further rise in Ca

]|

and AA inside the platelet, making it

prone to the aggregatory response.
The antiaggregatory action of PG^ appears to be due to the
stimulation of platelet adenylate cyclase, followed by an accumulation
of cAMP in the platelets (13). PGI2 is a potent stimulator of platelet
adenylate cyclase (13), and at present the most likely mechanism by
|
j
which cAMP elevation inhibits platelet aggregation is by holding Ca ,
in solution, in a cooplex with PGI2 within intracellular compartments.
I1
This leads to an inhibition of Ca mobilization within the platelet,
and hinderance of free AA formation (13).
Omega-3 Fatty Acids and Prostanoid Synthesis
At present there are two schools of thought as to the fate of the
cu-3 fatty acids and their effect on prostanoid synthesis. One is that
EPA can be utilized to form series 3 prostanoids (PGI^ and TXA^)(23-26)
probably by competitive inhibition of AA metabolism. PGI^ is said to
possess antiplatelet-aggregatory properties similar to those of PG^,
while TXA^ is said to be a less active promoter of platelet aggregation
than the corresponding series 2 substance TXA2 (24-26).
This theory has been challenged by other investigators, among them
Hornstra et al.(27), who regard EPA as a poor substrate for the cyclo-
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oxygenase which is responsible for the formation of the endoperoxide
intermediates. Evidence for this comes from studies in which rats and
rabbits were fed EPA-rich diets. Results failed to show any significant
production of PGI^ or TXA^ (27), and Hamazaki et al.(28) suggested that
the PG^-like substance produced, possessing antiplatelet-aggregation
properties, was most likely to be PG^.
Numerous investigators have found that feeding subjects a diet
rich in EPA or LNA caused a suppression in the synthesis of PG^ (24,
26,29,30) and TX^ (29-31). Several authors have reported that PGI2
production is decreased more than TX^ production (29,30). Other
investigators have found no significant change in either (10).
Explanations for the observation of decreased PGL^ and TXA2
production center around LNA being the preferred substrate for A6
desaturase, which limits the conversion of LA to AA, thereby limiting
the conversion of AA to PGl^ and TXA2 (23,24,26,27).
Recently, in support of the first hypothesis, Dyerberg et al.(32)
have found that human umbilical vessel walls are capable of utilizing
EPA for PGI-^ production, and that EPA inhibited PGI2 synthesis.
Furthermore, TXA2 production in human platelets was also found to be
inhibited by EPA. Marita et al.(33) found that the effects of EPA
differ with species. Eicosapentaenoic acid was added to cultures of
human, rat, rabbit and miniature pig smooth muscle cells, and bovine
endothelial cells. Ihey found that the rat and pig cells were unable to
convert EPA to PGI^, but that human, rabbit and bovine cells could
readily convert EPA to Al7-6-keto--PGF^Q,- the stable metabolite of
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PGI^. In rat cells, EPA also acted as an inhibitor of PG^? synthesis,
and showed little activity in inhibiting TX^ synthesis in platelets.
In human cells, however, EPA was not only easily converted to PGI^ by
vascular cells, but also blocked TXA2 synthesis in platelets. Thus, it
appears that the results of experiments involving EPA, and LNA, may be
subject to the selection of the experimental species.
Hamazaki et al.(28) reported an increase in the production of a
PG^-like substance in the aortas of rats fed a diet rich in LNA.
Considering the work of Dyerberg et al.(32) and Merita et al.(33), the
PG^-like substance may have been PGI3• Morita et al.(33), however,
found smooth muscle cells of rats were unable to form PGI^ from EPA.
Linolenic Acid and Cardiovascular Disease
Possible effects of LNA on the cardiovascular system were first
brought to the attention of the medical proffession when, in 1958,
Rutstein et al.(34) reported that the intracellular deposition of lipid
in tissue cultures of human aorta cells could be inhibited by LNA.
This finding stimulated a research interest in LNA, and linseed oil (a
major source of LNA), which continued throughout the 1960's, but waned
when greater success in research was obtained using LA.
In recent years, interest in LNA has been revived due to observa
tions involving the longer chain OJ-3 fatty acid, EPA. Most of the
interest surrounding the possible effects of LNA were centered around
its influence on platelet aggregation. In 1964, Owren et al.(35)
proposed that the increasing incidence of postoperative thrombosis and
nyocardial infarction may be related to a lack of dietary LNA. He
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furthermore demonstrated that linseed oil in moderate dosage reduced
the tendency to thrombose (35,36). Using dosages of 20 ml per day,
normal platelet adhesiveness was acquired by subjects with diabetes and
familial hypercholesterolemia within 3 days, and 5 ml per day produced
similar results within seven days. A single dose of 30 ml was reported
to bring about normal platelet adhesiveness after only 12 hours (35).
Similar results were recorded using 997> pure LNA (35).
Other researchers quickly attempted to reproduce Owren's results,
but with minimal success. Borchgrevink et al.(37) tried dosages of 10,
20 and 30 ml of linseed oil per day in patients with recent or
impending myocardial infarction. No changes were observed except for an
insignificant reduction in platelet adhesiveness with 30 ml of linseed
oil per day after four weeks.
In an attempt to settle the issue of the effect of LNA on platelet
adhesiveness, a large scale study was conducted in Norway in 1965.
Thirteen thousand male subjects between the ages of 50 and 59 years
volunteered to take 10 ml of linseed oil each day for one year (38). At
the end of the study, however, no significant difference was observed
in platelet adhesiveness. When these results were released, interest in
LNA began to decline rapidly.
Mire recently, interest in LNA has been stimulated through
research involving fish oil, a najor source of EPA. Eskimos have been
of great interest to investigators of heart disease for a number of
years. Although their diet is high in animal fat and protein and low in
carbohydrate (39), they continue to have a low incidence of coronary
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heart disease (39,40). They have been found to have a prolonged
bleeding time (41) and lower serum cholesterol and triglyceride levels
than their Caucasian counterparts (39,40). Analysis of the Eskimo diet
reveals it is rich in EPA due to the high consumption of fish (42). It
has been suggested that the low incidence of coronary heart disease may
result, in part, from their high intake of EPA, leading to an anti
thrombotic state in which an active PGI^ and an inactive TKA^ may be
formed (39,43).
Since fish oil is a good source of EPA, researchers began to use
this oil as their source of EPA. As results began to appear, it was
not long before interest in LNA was revived. Vas Dias et al.(40) found
that both linseed and fish oils lowered platelet aggregation more than
corn or coconut oils in four groups of six New Zealand white rabbits.
After 60 days of feeding at 60 g/kg/day, platelet aggregation was
significantly lower in the groups fed LNA and EPA. These changes were
accompanied by increased platelet lipid content of 20:5u>3 and a
decreased 20:4uo6 content. Similar results were obtained by Goodnight
et al.(44,45) and Ishinaga et al.(ll) in human subjects. Goodnight et
al.(44,45) also reported a reduction in plasma cholesterol and
triglyceride levels in subjects fed salmon oil. Bronsgeest-Schoute et
al.(42), after feeding 52 human subjects doses of 1.4, 2.3, 4.1 and
8.2 g of EPA each day for four weeks, reported a significant decrease
in serum triglyceride and very low-density lipoprotein levels, but no
significant change in serum total cholesterol and higjh-density lipo
protein cholesterol levels. Kobatake et al. (46) observed a decrease in
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serum total cholesterol and an increase in serum high-density lipo
protein cholesterol in rats fed a diet of 3% squid liver oil (75% EPA).
Research in the area of

CJ-3

fatty acids and their effects on

blood pressure, although still at an early stage, has indicated that
there may be a relationship between the two. A study by Scherhag et al.
(24,26) was one of the first in this area. They fed rats a diet in
which the total fat intake accounted for 25 percent of the total energy
intake. The fat composition was comprised of varying amounts of
saturated fat, oleic acid, LA, and cod liver and linseed oils. The rats
were fed these diets for six weeks, and after this period of time the
systolic blood pressure was found to be significantly elevated in five
of the seven test groups, including those fed 2.5 and 5.0% linseed and
cod liver oils respectively. These results my not apply to the human
situation if LNA and EPA can be utilized by human cells to form an
active PGI^ as reported by Morita et al.(33). Ifest et al.(10), in the
only human study available to date, found no significant change in
arterial blood pressure after feeding ten healthy subjects 30 ml of
linseed oil each day for four weeks.
Since PG^ and

were unknown substances In the 1960's, they

are now being implicated as being involved in the effects of the

GJ-3

fatty acids on the cardiovascular system. A nunber of investigators
have reported that an increase in dietary LNA or EPA caused a decrease
in the synthesis of PG^ and TXA^ (24-31). Since LNA is the precursor
of EPA it my be reasonable to assume that LNA would yield similar
results as EPA, as LNA is converted to EPA in human cells (7-11).

CHAPTER TW3
METHOD AND MATERIALS
Eight healthy male lacto-ovo-vegetarian subjects, aged 22 to 53
years (averaging 28.0 1" 3.6 years), were fed 45 ml of linseed oil (46%
LNA and 13% LA) each day for four weeks. No standard diet was given,
except that they restrict the intake of visible fats to a minimum, and
avoid fried foods. Subjects were otherwise asked to follow their usual
diet throughout the test period. Vitamin E supplementation of 400 I.U.
was given twice a week to subjects not already taking a supplement.
Subjects were also requested to avoid all non-steroidal antiinflam
matory and antihypertensive medications (appendix 1).
An initial diet history was taken prior to the commencement of the
study, so as to keep the total fat and energy intakes as close to
normal as possible throughout the study. Diet histories were repeated
at 2 and 4 weeks. Arterial blood pressures were recorded at weekly
intervals during the study by a trained public health scientist using
the standard cuff and mercury manometer technique. Subjects were kept
quietly seated for five minutes prior to the recording of blood
pressures. Body weights were also taken at weekly intervals, using a
beam balance scale.
Fasting 10 ml samples of blood were collected at 0, 2 and 4 weeks.
Samples were drawn into plastic syringes from an uncuffed arm, and
immediately transferred into chilled tubes containing EDIA-aspirin
solution as used by Morris et al.(47). Blood samples were then centrifuged at 4000 rpm for 15 minutes to yield Platelet Poor Plasma (PPP).
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Estimation of Plasma Total Phospholipid Fatty Acid Composition
Two ml of chloroform and 4 ml of methanol "were added to 2 ml of
PPP, then filtered. The residue was rinsed with 4 ml of chloroform /
methanol (1:2 v/v), then rinsed with another 2 ml of the chloroform /
methanol solution. Four ml of chloroform and 5.6 ml of deionized water
were added to the filtrate to form a two phase solution. This solution
was clarified by centrifugation at 1000 rpm for 5-10 minutes. The top
layer was removed and discarded, leaving the chloroform layer with the
extracted lipids. This was evaporated to dryness under nitrogen gas.
The dry lipid extract was then redissolved in n-hexane, added to a
200 grade silica gel column, and washed with 40 to 45 ml of chloroform.
The chloroform-lipid extract was collected and discarded. The column
was then washed with 40 to 45 ml of methanol, and these methanol
washings were collected in a round-bottom flask. The methanol-lipid
extract was rotary evaporated to dryness, leaving the dry phospholipid
extract. The extract was redissolved in 1 to 2 ml of boron trifluoride
in methanol, transferred to a screw cap vial, and heated for 30 minutes
at 95° C. The reaction mixture was immediately cooled and 1 to 2 ml of
deionized water added. The mixture was immediately extracted twice
with n-hexane, and evaporated to dryness under nitrogen gas.
The final dry phospholipid extract was redissolved in 100 pi of
n-hexane and injected into a Varian 3700 Gas Chromatograph with a
Varian CDS IIIL Computer and Servocorder SR 6253 for analysis.
Estimation of Plasma 6-Keto-PGF-^ a< and

TXBQ

by Radioirnmunoassay

PPP samples were prepared from collected EDIA-blood. One-tenth ml
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aliquots of samples were added to 0.1 ml of H -labelled tracer, 0.2 ml
of gamma globulin and 0.1 ml of the corresponding antibody (6-ketoPGFla

or

• After addition of the antibody, the tubes were

incubated for 16 hours at 4° C. After the incubation period, the tubes
were placed in an ice bath and 0.5 ml of polypropylene glycol (25% w/v)
added to each tube and vortexed. The tubes were immediately centrifuged
at 4° C for 30 minutes at 3400 rpm. After centrifugation, the supernatants were decanted and discarded, and the precipitates redissolved
in 1 ml of distilled water. The resuspended precipitates were then
transferred to polypropylene scintillation vials containing 10 ml of
modified Bray's solution (100 g Naphthalene, 7 g Dimethyl-POPOP-1,4bis-[2-(4-Methyl-5-Phenyloxazolyl)]-Benzene, and 0.3 g 2,5-Diphenyloxazole made up to 1 liter with dioxane), and counted for 10 minutes in
a Beckman LS-250 Liquid Scintillation Counter.
Estimation of Plasma Cholesterol and Triglyceride Levels
Plasma cholesterol and triglyceride estimations were performed on
the PPP samples by Bio-Science Laboratories, Van Nuys, California.
Plasma cholesterol levels were estimated spectrophotometrically after
the cholesterol-containing extract had been added to ferric chloride,
and acetic and sulfuric acids. Plasma triglyceride levels were
estimated by direct measurement of glycerol after separation from the
phospholipids. After saponification, the free glycerol was oxidized
with sodium metaperiodate, and the resulting formaldehyde formed was
reacted with chromotropic acid, yielding a highly colored compound
which was measured spectrophotometrically.
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Statistical Analysis
Statistical analysis was determined by the paired student's t-test
(two-tailed) as performed by the Department of Biostatistics, Loma
Linda University, Loma Linda, California, using the Statistical Package
for the Social Sciences. All statistical tests were considered
significant at the pO.05 level.

After seeing the results for week 2 of the diet study, it was
decided to add a four week follow-up to the original methodology of the
study to see if the plasma 6-ketO-PGF-^ and TXB2 levels returned to the
baseline levels after the completion of the four week dietary supple
mentation period.

CHAPTER THREE
RESULTS
Eight healthy male lacto-ovo-vegetarian subjects were fed 45 ml of
linseed oil (46% LNA and 13% LA) each day for four weeks as a supple
ment to their regular diet. The dietary total fat and LA content were
not affected by the experimental change in the diet (Table 2), but as
expected, significant increases in the LNA content (p<0.001) and the
P/S ratio of the diet were observed. Body weight of the subjects did
not change throughout the test period. No adverse effects were observed
in, or reported by, the subjects as a result of the linseed oil
supplementation.
Arterial Blood Pressure
Analysis of systolic and diastolic blood pressures revealed a
significant elevation of the systolic blood pressure between weeks 0
and 1 (Mean ± SEM: 106.5 ± 2.7 nnHg to 114.0 t 3.7 imfig; p<0.003)
(figure 5 and appendix table 1). Diastolic blood pressure for the same
period was also observed to rise (69.8 "t 3.0 mrHg to 74.3 i 2.9 mnHg),
but not significantly. Both systolic and diastolic blood pressures,
however, returned to approximately the initial levels by week 2, 107.3
± 2.6 nnHg (p<0.02) and 69.3 1" 2.9 mrHg, respectively.
Plasma 6-Reto-PGFn

and TXBz0 Levels

A significant alteration in both plasma 6-keto-PGF-^ , and TXB2
levels occurred during the study. The plasma 6-keto-PGF-^a increased
from 60.13 t 8.50 pg/ml to 97.88 ± 9.94 pg/ml (p<0.001) In the first
two weeks, continued this upward trend to 288.75 "t 33.44 pg/ml
(p<0.001) at week 4, and remained at that level four weeks after the
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Table 2. The average composition of the diet of the human subjects
before (week 0) and after (weeks 2 and 4) supplementation with 45 ml
of linseed oil. All values are the mean ± SEM. Those values sharing
the sane superscript are significantly different from each other.
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Figure 5. The effect of dietary linseed oil supplementation on
systolic and diastolic arterial blood pressure in human subjects.
All values are the mean t SEM.
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completion of the study (figure 6 and appendix table 2).
Plasma TXE^ levels showed an unexpected change. Between weeks 0
and 2, a significant increase was observed (397.50 T 71.66 pg/ml to
1576.25 ± 282.61 pg/ml; p<0.005), but then decreased to 814.29 t 122.74
pg/ml (p<0.02) at week 4. Analysis of samples taken four weeks after
the completion of the study indicated that the TXB2 levels were
approaching baseline values (figure 7 and appendix table 3).
The 6-keto-PGF-j^ / TXB^ ratios displayed a significant decrease in
the first two weeks (0.157 1" 0.022 to 0.072 1" 0.011; p<0.003), and then
increased over the next two weeks to 0.377 1" 0.069 (p<0.003) (figure 8
and appendix table 4).
Plasma Total Phospholipid Fatty Acid Composition
Analysis of plasma samples by gas-liquid chromatography revealed
several significant shifts in the phospholipid fatty acid composition.
The 18:2UJ6 levels were found to decrease from 23.63 1" 0.93% to 19.79
1.73% (p<0.04) during the four week diet study. The 20:4^6 levels also
decreased, but the change was statistically insignificant (Table 3). A
significant increase was observed for both 18:3^3 and 20:5^3 levels
(Table 3). The 18:3^3 levels increased from 0.94 1" 0.12% to 2.73 t
0.53% (p^0.002) during the four week period, and the 20:5^3 levels
increased from 0.73 t 0.18% to 2.45 + 0.44% (p^0.02) during.the same
period. The 22:5 w 3 fatty acid levels exhibited a statistically
insignificant increase in concentration.

40

Figure 6.

The effect of dietary linseed oil supplementation on plasma

6-keto-PGF-^ levels in human subjects. All values are the mean "t SEM.
Vc 4 v?eeks after the conpletion of the dietary supplementation period.
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Figure 7. The effect of dietary linseed oil supplementation on plasma
TXB^ levels in human subjects. All values are the mean "t SEM.
* 4 weeks after the completion of the dietary supplementation period.
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Figure 8. The effect of dietary linseed oil supplementation on the
plasma 6-keto-PGF-^^ /TXE^ ratio in human subjects. All values are the
mean "t SEM.
* 4 weeks after the completion of the dietary supplementation period.
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Table 3. The average plasma total phospholipid fatty acid composition
(7C) of human subjects before (week 0) and after (weeks 2 and 4)
dietary supplementation with 45 ml of linseed oil. All values are the
nean "t SEM. Those values sharing the same superscript are significantly
different from each other.
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CHAPTER FOUR
DISCUSSION
Changes observed in the plasma total phospholipid fatty acid
composition of the subjects after feeding of 45 ml of linseed oil each
day for four weeks are consistent with earlier observations by other
researchers in humans (10), rabbits (40) and rats (7-9). We observed
shifts in the 18:2co6, 18:3co3, 20:4co6 and 20:5 co 3 fatty acid levels.
Significant increases in the 18:3 to 3 (p<0.02) and 20:5 to 3 (p<0.02)
levels were found to occur during the four week period, while 18:2a;6
levels were found to decrease (p<0.05). A decrease was also noted in
the 20:4co6 fatty acid levels, but this shift was not significant.
Significant shifts in the 22:4to 6, 22:5 to 3 and 22:6 to 3 levels, as
reported by other researchers, were not observed. Marshall and Johnston
(7), Hwang and Carroll (9) and Vas Dias et al.(40) have reported a
significant increase in the 22:5co3 and 22:6 to 3 fatty acid levels in
tissues of rats and rabbits fed diets rich in LNA. Mest et al.(10)
reported a significant increase in the 22:6 co 3 levels in human subjects
fed a diet rich in LNA. In addition to these changes, Marshall and
Johnston (7) observed a significant decrease in 22:4to6 levels.
The changes in fatty acid composition can be explained In terms of
the dietary intake of LA and LNA. The to-3 fatty acids are the
preferred substrates of A6 desaturase, the rate-limiting enzyme of the
fatty acid desaturase and elongation system (7). By increasing the LNA
intake, the LA/LNA ratio is decreased, and presents the A6 desaturase
with an increased supply of its preferred substrate. The result is an
increase in the subsequent longer chain derivatives of LNA (20:5co3,
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22:5cu3 and 22:6w3) (7,9,40), and a decrease in the longer chain
derivatives of LA (20:4 A;6 and 22:4 OJ 6) (7,9,48,49).
Our finding of an elevation in plasma 6-keto-PGF^ (p<0.001)
during the diet study is consistent with the findings of Hamazaki et
al.(28) . They observed an increase in the production of a PG^-like
substance by aorta tissue of rats fed a diet rich in EPA, although
kforita et al. (33) found no conversion of EPA to PGI^ by smooth muscle
cell cultures of rats. Our finding seems to be in conflict with the
results of most researchers (24,26,29,30) who have reported a decrease
in PGI2 production by various tissues of subjects fed diets rich in LNA
and EPA. When the results of Dyerberg et al.(32) and Murita et al.(33)
are considered, it suggests that PGI2 synthesis is suppressed in
subjects fed diets rich in to-3 fatty acids, and that the PG^-like
substance may be PGI^. The aforementioned researchers have reported the
production of PGI^ in human cells in the presence of EPA, Dyerberg et
al. (32) in umbilical vessels, and Mbrita et al.(33) in smooth muscle
cells.
If EPA is not converted to PGI^ an alternate explanation could be
offered to account for the increase in plasma 6-keto-PGF^ levels. It
may be related to the rate of incorporation of LNA and EPA into aorta
tissue, the major site of PGI2 production (12) . Since the turnover of
phospholipids in the cell membrane of aorta tissue is very slow (50),
the incorporation of LISA and EPA into the cell menbrane at the expense
of LA and AA would also be slow. A gradual release of free LA and AA
would result. Since AA is the precursor for PGI2 synthesis (12), this
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could explain the gradual increase in the 6-keto-PGF^^ levels.
The results of the plasma TXE^ levels were suprising when conpared
to those of other researchers. We found a significant increase in TXE^
levels after the first two weeks on the test diet (p<0.005), followed
by a decrease between weeks 2 and 4 (p<0.02). This decrease continued
towards the baseline levels in the weeks following the completion of
the test period, as indicated by the four week follow-up.
The results may be explained by the rate of incorporation of LNA
and EPA into the cell membrane of the blood platelets, the major site
of TX^ synthesis (12). The life span of blood platelets is very short,
ranging from about six hours to a couple of days, and a complete
turnover of all platelets in the body takes place in about ten days
(50). As the old platelets are metabolized, free LA and AA are released
providing the substrate necessary for TXA2 synthesis. New platelets are
formed incorporating LNA and EPA into their structure at the expense of
LA and AA. This hypothesis would account for the peak and subsequent
decline in plasma TXE^ levels observed in our subjects. Mast
researchers have only reported a decrease in TXE^ levels in subjects
fed diets rich in LNA or EPA (29-31).
Fluctuations were observed in arterial blood pressures during the
study. The observation of a significant increase in systolic blood
pressure during the first week is consistent with the findings of
Dusing et al.(24,26). These investigators reported that rats given
diets supplemented with linseed and cod liver oils, in varied amounts
of 2.5% and 5% of total energy, had significantly raised arterial blood
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pressures than the control group. This elevation in blood pressure may
be related to the plasma TX^ levels, since the increase coincides with
an increase in plasm TXI^ levels and a decrease in plasm 6-keto-PGF-^
to TXB2 ratios at week 2. The results revealed an insignificant
increase in arterial blood pressure at the end of the four week study.
An interesting observation during the study was that the subjects
appeared to bleed more freely from the puncture wound after the removal
of the syringe for blood sampling at weeks 2 and 4 than at week 0. This
observation, although not physically measured, is consistent with the
findings of Owren (35,36) that a diet rich in linseed oil reduced
platelet adhesiveness in subjects with diabetes and familial hypercholesterolemia.
In conclusion, the data from this study seems to indicate that
a-linolenic acid my have some beneficial long-term effects, as it
resulted in the increased production of 6-keto-PGF-^ and. 6-keto-PGF^a /
TXB2 ratios. However, caution must be exercised in using LNA for the
treatment and prevention of cardiovascular disease due ot the mrked
increases in arterial blood pressures and plasm TXB2 levels, and
decrease in 6-keto-PGF^ /TXf^ ratios during the first two weeks of
linseed oil supplementation in the diet. Some of our results may differ
from those of earlier studies because we used a higher dose of linseed
oil (45 ml) than used in other studies, and our subjects were lactoovo-vegetarians.

CHAPTER FIVE
SUMMARY
Eight healthy male lacto-ovo-vegetarian subjects "were fed a diet
rich in LNA for four weeks. Arterial blood pressure and body weight
were recorded each week. Blood samples were taken every second week
for estimation of plasma 6-keto-PGF^ , TXB2, total cholesterol and
triglyceride levels, and plasma total phospholipid fatty acid
composition.
Systolic blood pressure was observed to increase during week 1
(p^0.002), but then decreased during week 2 (p<0.02). Diastolic blood
pressure followed a similar pattern, but the increase was not
significant. There was an insignificant increase in both systolic and
diastolic blood pressures after four weeks.
Plasma phospholipid fatty acid analysis revealed significant
increases in 18:3u>3 (p<0.02) and 20:5u>3 (p^0.02) fatty acid levels,
and a significant decrease in the 18:2006 (p<0.04) fatty acid levels.
Plasma 6-keto-PGF-^ levels increased significantly (p<0.001) during
the four week period. A significant increase in plasma TXB2 ^eve-'-s
occurred during the first two weeks (p<0.005), then decreased in the
following two weeks (p<0.02). However, at the end of the four weeks the
plasma TXB2 level was still significantly elevated (p<0.02). No
significant change was found in either the plasma total cholesterol or
triglyceride levels.
The data from this study seems to indicate that LNA may have some
beneficial long-term effects, however caution must be exercised in
using LNA for the treatment and prevention of cardiovascular disease
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due to possible increases in arterial blood pressure and plasma TXB^
levels.
The results of this study give rise to suggestions for further
research. The suggestions involve the repetition of this study, but
with some nodifications. Firstly, investigation of the effect of LNA. on
platelet clotting times and thrombotic tendency is of interest. The
other suggestions involve using different groups of subjects. It may be
of benefit to repeat this study using non-vegetarians, hypercholesterolemlc patients, and 50 to 59 year old males as subjects to see if
there is a difference in the metabolism of WA in these groups compared
to the subjects used in this study.
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APPENDIX
The following list of medications should be avoided while
participating in the dietary linolenic acid study.
ANTI-INFLAMMATORY MEDICATIONS
Aspergum

Clinoril

Nalfon

Aspirin

Colchicine

Oxalid

A.S.A.

Disalcid

Phenylbutazone

Azathioprin

Ecotrin

Sodium Salicylat

Azolid

Empirin

Solganal

Azolid A

Indomethacin

Tandearil

Butazolidin

Measurin

Tolectin

Butazolidin Alka

Myochrysine

Tylenol

ANTI-HYPERTENSIVE MEDICATIONS
Aldactazide

Apresazide-100/50

Diucardin

Aldoclor-150

Apresoline

Diupres-500

Aldoclor-250

Apresoline-Esidrix

Diuril

Aldomet

Aquatag

Diutensin

Aldoril-15

Aquatensin

Diutensin-R

Aldoril-25

Catapres

Dyazide

Aldoril D30

Cinnasil

Enduronyl

Aldoril D50

Combipres 0.1

Enduronyl Forte

Alkarau

Combipres 0.2

Esidrix

Anhydron

Corgard

Esimil

Apresazide-25/25

Demi-Regroton

Eutonyl

Apresazide-50/50

Dibenzline

Eutron
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ANTI-HYPERTENSIVE MEDICATIONS (Continued)
Exna

Mietatensin 2 mg

Regroton

Exna-R

Metatensin 4 mg

Releserp

Harmonyl

Minipress

Renese

Hiserpia

Minizide 1

Renese-R

Hiwalfia

Minizide 2

Reserjen

HydroDIURIL

Minizide 5

Reserpoid

Hydromax

Maderil

Ru-Hy-T

Hydromax-R

Naquival

Saluron

Hydropres-25

Naturetin

Salutensin

Hydropres-50

Nipride

Salutensin-Demi

Hydro-Z

Oretic

Sandril

Hygroton

Oreticyl-25

S-Aqua

Hyper-Raw

Qreticyl-50

SER-AP-ES

Inderal

Oreticyl-Forte

Serfolia

Inderide 40/25

Proaqua

Serpanray

Inderide 80/25

Raudixin

Serpasil

Ismelin Sulfate

Rau-sed

Serpasil-Aresoline #1

Jen-Diril

Rauserpin

Serpasil-Aresoline #2

Lasix

Rautensin

Serpasil-Esidrix #1

Lemiserp

Rauval

Serpasil-Esidrix #2

Lonitron

Rauwiloid

Serpate

Lopressor

Rauzide

Marazide

Regitine
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Table 1. The effect of dietary linseed oil supplementation on
systolic and diastolic arterial blood pressure in human subjects.
All values are the mean "t SEM. Those values sharing the same
superscript are significantly different from each other.
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WEEK

BLOOD PRESSURE (nnfig)
SYSTOLIC

DIASTOLIC

0

106.5 ± 2.7a

69.8 t 3.0

1

114.0 + 3.7a'b

74.3 t 2.9

2

107.3 + 2.6b

69.3 + 2.9

3

108.6

4

110.3 t 2.5

ap<0.003
bp<0.02

3.0

t

73.1 t 3.1
72.8 t 2.6
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Table 2. The effect of dietary linseed oil supplementation on plasma
6-keto-PGF^Q, levels in human subjects. All values are the mean t SEM.
Those values sharing the same superscript are significantly different
from each other.

WEEK

6-KETO-PGFla. (pg/ml)

0

60.13 +8.50 a '°

2

97.88 + 9.94 a,b

4

288.75 + 33.44 b,c

8*

298.75 t 5.84
ablCp«0.001

*4 weeks after the completion of the dietary
supplementation period.
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Table 3. The effect of dietary linseed oil supplementation on plasma
TXB2 levels in human subjects. All values are the mean ± SEM. Those
values sharing the same superscript are significantly different from
each other.

WEEK

TXB2 (PS/"11)

0

397.50 + 25,34a'°

2

1576.25 + 282.61a'b

4

814.29 t 122.74b'°

8*

567.50 + 50.02
ap<0.005
b,cp<0.02

*4 weeks after the completion of the dietary
supplementation period.
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Table 4. The effect of dietary linseed oil supplementation on the
plasma 6-keto-PGFlQ;/TXB^ ratio in human subjects. All values are
the mean t SEM. Those values sharing the same superscript are
significantly different from each other.

WEEK

6-KETO-PGFla,/TXB0

0

0.157 ± 0.022a,c

2

0.072 t 0.011a'b

4

0.377 t 0.069b,c

8*

0.601 + 0.077
ap<0.003
bp<0.004
cp<0.03

*4 weeks after the completion of the dietary
supplementation period.

Table 5. The effect of dietary linseed oil supplementation on plasma
cholesterol levels in human subjects. All values are the mean ~t SEM.

yiiTRg

PLASMiY CHOLESTEEOL (mg/dl)

0

132.88 + 12.53

2

136.88 + 13.38

4

132.00 + 11.38

Table 6. The effect of dietary linseed oil supplementation on plasma
triglyceride levels in human subjects. All values are the mean ± SEM.
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prer

PLASMA TRIGLYCERIDE (me/dl)

0

56.25 + 4.42

2

69.13 + 7.28

4

61.88 + 4.31

